NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
-9.25%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$153M
AUM Growth
+$153M
(+20%)
Cap. Flow
+$32.6M
Cap. Flow
% of AUM
21.26%
Top 10 Holdings %
Top 10 Hldgs %
70.63%
Holding
52
New
17
Increased
3
Reduced
8
Closed
14
Top Buys
| 1 |
Novartis
NVS
|
$14.4M |
| 2 |
CELG
Celgene Corp
CELG
|
$14.1M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12.2M |
| 4 |
SHPG
Shire pic
SHPG
|
$10.7M |
| 5 |
AstraZeneca
AZN
|
$8.2M |
Top Sells
| 1 |
GSK
GSK
|
$14.9M |
| 2 |
Pfizer
PFE
|
$10.9M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$6.02M |
| 4 |
Neurogene
NGNE
|
$4.54M |
| 5 |
LCI
Lannett Company, Inc.
LCI
|
$4.44M |
Sector Composition
| 1 | Healthcare | 92.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SHPG
1
DELISTED
Shire pic
SHPG
| $22.1M | 12.98% | 130,000 +63,000 | +94% | +$10.7M |
|
|
2
Novartis
NVS
$245B
| $14.4M | 8.45% | +198,000 | New | +$14.4M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $14.1M | 8.28% | +122,000 | New | +$14.1M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $12.2M | 7.17% | +100,000 | New | +$12.2M |
|
|
5
Pfizer
PFE
$141B
| $10.3M | 6.06% | 318,051 -336,000 | -51% | -$10.9M |
|
|
6
AstraZeneca
AZN
$248B
| $8.2M | 4.8% | +300,000 | New | +$8.2M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $8.09M | 4.74% | +500,000 | New | +$8.09M |
|
|
KITE
8
DELISTED
Kite Pharma, Inc.
KITE
| $6.73M | 3.94% | +150,000 | New | +$6.73M |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $6.18M | 3.62% | +165,000 | New | +$6.18M |
|
10
Minerva Neurosciences
NERV
$16.5M
| $5.79M | 3.4% | +492,958 | New | +$5.79M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $4.64M | 2.72% | +120,000 | New | +$4.64M |
|
|
XLRN
12
DELISTED
Acceleron Pharma Inc.
XLRN
| $4.54M | 2.66% | 178,000 -39,817 | -18% | -$1.02M |
|
13
Insmed
INSM
$28.8B
| $4.26M | 2.5% | 322,044 | – | – |
|
|
EIGR
14
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.07M | 1.8% | 263,600 -400 | -0.2% | -$4.66K |
|
15
Abeona Therapeutics
ABEO
$350M
| $2.76M | 1.62% | 568,573 +246,964 | +77% | +$1.2M |
|
|
ADMS
16
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $2.56M | 1.5% | 151,670 -127,070 | -46% | -$2.15M |
|
17
FibroGen
FGEN
$47.8M
| $2.48M | 1.45% | 116,000 -11,680 | -9% | -$250K |
|
|
TRVN
18
DELISTED
Trevena, Inc.
TRVN
| $2.35M | 1.37% | 398,849 +100,000 | +33% | +$588K |
|
|
TVRD
19
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $2.32M | 1.36% | +250,000 | New | +$2.32M |
|
20
Ascendis Pharma
ASND
$11.8B
| $2.02M | 1.19% | 100,000 -46,200 | -32% | -$935K |
|
|
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
| $1.82M | 1.07% | 150,000 -110,000 | -42% | -$1.34M |
|
|
CNCE
22
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $1.73M | 1.01% | 167,866 | – | – |
|
|
PRTK
23
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $1.54M | 0.9% | +100,000 | New | +$1.54M |
|
24
Sangamo Therapeutics
SGMO
$157M
| $1.53M | 0.9% | +503,000 | New | +$1.53M |
|
|
ADXS
25
DELISTED
Advaxis, Inc.
ADXS
| $1.43M | 0.84% | 200,000 | – | – |
|